Cargando…
A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS Mutants
Kirsten-RAS (KRAS) has been the target of drugs because it is the most mutated gene in human cancers. Because of the low affinity of drugs for KRAS mutations, it was difficult to target these tumor genes directly. We found a direct interaction between KRAS G12V and tumor suppressor novel H-REV107 pe...
Autores principales: | Han, Chang Woo, Jeong, Mi Suk, Ha, Sung Chul, Jang, Se Bok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352977/ https://www.ncbi.nlm.nih.gov/pubmed/32486141 http://dx.doi.org/10.3390/cancers12061412 |
Ejemplares similares
-
Oncogenic KRAS: Signaling and Drug Resistance
por: Kim, Hyeon Jin, et al.
Publicado: (2021) -
Understand KRAS and the Quest for Anti-Cancer Drugs
por: Han, Chang Woo, et al.
Publicado: (2021) -
Structure, signaling and the drug discovery of the Ras oncogene protein
por: Han, Chang Woo, et al.
Publicado: (2017) -
H-rev107 Regulates Cytochrome P450 Reductase Activity and Increases Lipid Accumulation
por: Tsai, Fu-Ming, et al.
Publicado: (2015) -
Phospholipase A/Acyltransferase enzyme activity of H-rev107 inhibits the H-RAS signaling pathway
por: Wang, Chun-Hua, et al.
Publicado: (2014)